Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Alzheimer's Disease
Interventions
DRUG

AAB-003 (PF-05236812)

0.5 mg/kg AAB-003, IV

DRUG

AAB-003 (PF-05236812)

1 mg/kg AAB-003, IV

DRUG

AAB-003 (PF-05236812)

2 mg/kg AAB-003, IV

DRUG

AAB-003 (PF-05236812)

4 mg/kg AAB-003, IV

DRUG

AAB-003 (PF-05236812)

8 mg/kg AAB-003, IV

Trial Locations (21)

20814

Foers Medical Arts Pharmacy, Bethesda

20850

CBH Health, LLC, Rockville

30308

Atlanta Center for Medical Research, Atlanta

33009

MD Clinical, Hallandale

34471

Munroe Regional Medical Center, Ocala

Renstar Medical Research, Ocala

Trinity Care Solutions, Ocala

34481

Advanced Imaging of Ocala, Ocala

49048

Borgess Medical Center, Kalamazoo

Borgess Research Institute, Kalamazoo

KNI Southwest Michigan Imaging Center, LLC, Kalamazoo

63044

DePaul Health Center-MRI Department, St Louis

63141

Millennium Psychiatric Associates, LLC, Creve Coeur

143914

Konkuk University Medical Center, Department of Neurology, Seoul

1350710

Samsung Medical Center, Department of Neurology, Seoul

07724

Memory Enhancement Center of America, Inc., Eatontown

07755

Central Jersey Radiology, Oakhurst

463-707

Seoul National University Hospital, Department Neurology, Seongnam-si

400-711

Inha University Hospital, Department of Neurology, Incheon

136-705

Korea University Anam Hospital IRB, Seoul

138-736

ASAN Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

INDUSTRY

lead

Pfizer

INDUSTRY

NCT01369225 - Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter